CA3112519A1 - Indazole carboxamides as kinase inhibitors - Google Patents

Indazole carboxamides as kinase inhibitors Download PDF

Info

Publication number
CA3112519A1
CA3112519A1 CA3112519A CA3112519A CA3112519A1 CA 3112519 A1 CA3112519 A1 CA 3112519A1 CA 3112519 A CA3112519 A CA 3112519A CA 3112519 A CA3112519 A CA 3112519A CA 3112519 A1 CA3112519 A1 CA 3112519A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
substituted
compounds
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3112519A
Other languages
English (en)
French (fr)
Inventor
Junqing Guo
Carolyn Diane Dzierba
Amy C. HART
John E. Macor
William J. Pitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA3112519A1 publication Critical patent/CA3112519A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3112519A 2018-09-13 2019-09-12 Indazole carboxamides as kinase inhibitors Pending CA3112519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730611P 2018-09-13 2018-09-13
US62/730,611 2018-09-13
PCT/US2019/050721 WO2020056074A1 (en) 2018-09-13 2019-09-12 Indazole carboxamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3112519A1 true CA3112519A1 (en) 2020-03-19

Family

ID=68073172

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112519A Pending CA3112519A1 (en) 2018-09-13 2019-09-12 Indazole carboxamides as kinase inhibitors

Country Status (14)

Country Link
US (1) US12084426B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849969B1 (cg-RX-API-DMAC7.html)
JP (1) JP7434294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793119B1 (cg-RX-API-DMAC7.html)
CN (1) CN112673001B (cg-RX-API-DMAC7.html)
AU (1) AU2019339355A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004310A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112519A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190759A1 (cg-RX-API-DMAC7.html)
ES (1) ES2945220T3 (cg-RX-API-DMAC7.html)
IL (1) IL281371A (cg-RX-API-DMAC7.html)
MX (1) MX2021002617A (cg-RX-API-DMAC7.html)
SG (1) SG11202102406XA (cg-RX-API-DMAC7.html)
WO (1) WO2020056074A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
KR20230100646A (ko) 2021-12-24 2023-07-05 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−7ニコチン性受容体リガンド並びにその製造及び使用
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR20130077390A (ko) 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
EA024939B1 (ru) 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
WO2013124169A1 (en) 2012-02-21 2013-08-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
US10933068B2 (en) 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
US10836770B2 (en) * 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102906523B1 (ko) 2018-09-13 2025-12-30 브리스톨-마이어스 스큅 컴퍼니 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
US12084426B2 (en) 2024-09-10
SG11202102406XA (en) 2021-04-29
KR102793119B1 (ko) 2025-04-07
US20210309633A1 (en) 2021-10-07
JP7434294B2 (ja) 2024-02-20
JP2022501334A (ja) 2022-01-06
KR20210060516A (ko) 2021-05-26
AU2019339355A1 (en) 2021-05-13
ES2945220T3 (es) 2023-06-29
MX2021002617A (es) 2021-05-12
IL281371A (en) 2021-04-29
EP3849969A1 (en) 2021-07-21
CN112673001A (zh) 2021-04-16
BR112021004310A2 (pt) 2021-05-25
EP3849969B1 (en) 2023-04-19
CN112673001B (zh) 2024-06-25
WO2020056074A1 (en) 2020-03-19
EA202190759A1 (ru) 2021-06-17

Similar Documents

Publication Publication Date Title
EP3849969B1 (en) Indazole carboxamides as kinase inhibitors
EP2802577B1 (en) Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
AU2018361249B2 (en) Aminoimidazopyridazines as kinase inhibitors
EP3849968B1 (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
US10301306B2 (en) Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
EP4037772B1 (en) Indazole carboxamides as kinase inhibitors